AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
20 Mar 2014 11:00 AM
RNS
Directorate Change
19 Mar 2014 03:00 PM
RNS
Director/PDMR Shareholding
12 Mar 2014 07:00 AM
RNS
AstraZeneca announces sale of Alderley Park site
03 Mar 2014 04:00 PM
RNS
Total Voting Rights
03 Mar 2014 07:00 AM
RNS
US FDA APPROVES BYDUREON? PEN
25 Feb 2014 06:24 PM
RNS
FDA Approves Orphan Drug Myalept
12 Feb 2014 03:30 PM
RNS
Director/PDMR Shareholding
11 Feb 2014 05:00 PM
RNS
Director/PDMR Shareholding
10 Feb 2014 05:30 PM
RNS
Director/PDMR Shareholding
07 Feb 2014 03:30 PM
RNS
Director/PDMR Shareholding
06 Feb 2014 07:00 AM
RNS
Pipeline Table
06 Feb 2014 07:00 AM
RNS
Final Results
05 Feb 2014 09:00 AM
RNS
Notice of Results
03 Feb 2014 04:30 PM
RNS
Total Voting Rights
03 Feb 2014 07:00 AM
RNS
AZ completes BMS diabetes acquisition
27 Jan 2014 10:30 AM
RNS
Holding(s) in Company
22 Jan 2014 07:00 AM
RNS
Xigduo approved in EU for type 2 diabetes
17 Jan 2014 10:42 AM
RNS
Replacement re block listing application
17 Jan 2014 07:00 AM
RNS
Block Listing Application
14 Jan 2014 07:00 AM
RNS
AstraZeneca provides strategy update at JP Morgan
13 Jan 2014 07:00 AM
RNS
US FDA APPROVES FARXIGAT (DAPAGLIFLOZIN)
09 Jan 2014 07:00 AM
RNS
US FDA Approval of Farxiga (dapagliflozin)
02 Jan 2014 04:00 PM
RNS
Total Voting Rights
27 Dec 2013 07:13 AM
RNS
AZ and Shionogi extend Crestor agreement
19 Dec 2013 02:00 PM
RNS
Director/PDMR Shareholding
19 Dec 2013 07:50 AM
RNS
AZ to acquire BMS share of diabetes assets
17 Dec 2013 06:13 PM
RNS
STATEMENT ON ESOMEPRAZOLE STRONTIUM LAUNCH IN US
13 Dec 2013 07:14 AM
RNS
Top Line Results From Phase III Study of Lesinurad
13 Dec 2013 07:00 AM
RNS
FDA Advisory Committee Recommends Dapagliflozin
12 Dec 2013 07:00 AM
RNS
FDA Advisory Committee Votes on Metreleptin
06 Dec 2013 07:00 AM
RNS
European Commission Approves Fluenz Tetra
02 Dec 2013 03:00 PM
RNS
Blocklisting Interim Review
02 Dec 2013 01:00 PM
RNS
Total Voting Rights
22 Nov 2013 01:42 PM
RNS
XIGDUO POSITIVE CHMP OPINION FOR TYPE 2 DIABETES
19 Nov 2013 07:00 AM
RNS
NDA for Naloxegol accepted by US FDA
01 Nov 2013 04:00 PM
RNS
Total Voting Rights
01 Nov 2013 01:45 PM
RNS
Director/PDMR Shareholding
31 Oct 2013 07:02 AM
RNS
US Court Decision in Pulmicort Respules Litigation
31 Oct 2013 07:01 AM
RNS
Marc Dunoyer Appointed Chief Financial Officer
31 Oct 2013 07:00 AM
RNS
3rd Quarter Results
30 Oct 2013 09:00 AM
RNS
Notice of Results
30 Oct 2013 07:00 AM
RNS
ASTRAZENECA ADVANCES BENRALIZUMAB TO PHASE III
22 Oct 2013 07:00 AM
RNS
AstraZeneca starts phase III study for selumetinib
15 Oct 2013 07:00 AM
RNS
Medimmune acquires Spirogen
07 Oct 2013 07:00 AM
RNS
MedImmune completes Amplimmune acquisition
01 Oct 2013 04:00 PM
RNS
Total Voting Rights
30 Sep 2013 07:01 AM
RNS
MAA FOR OLAPARIB ACCEPTED BY EMA
27 Sep 2013 07:00 AM
RNS
MAA APPLICATION FOR NALOXEGOL ACCEPTED
20 Sep 2013 12:54 PM
RNS
Fluenz Tetra receives positive CHMP opinion in EU
04 Sep 2013 07:00 AM
RNS
Starts phase III clinical programme for olaparib
AstraZeneca PLC, known as AZN on the London Stock Exchange (LSE), is an Anglo-Swedish multinational pharmaceutical and biotechnology company. Founded on April 6, 1999, AstraZeneca was formed through the merger of the Swedish Astra AB and the British Zeneca Group. The company's roots trace back to 1913, when Astra AB was established by a group of doctors and apothecaries in Södertälje, Sweden. Throughout the twentieth century, AstraZeneca grew into one of the largest pharmaceutical companies in the world. It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). Today, AstraZeneca operates in over 100 countries and employs around 83,000 people. As a member of the LSEG, AZN continues to shape the global healthcare landscape. The company is committed to defeating diseases that impact people's health.
UK 100